New Radiopharmaceuticals to Enter Market as R&D Activities Intensify

Over the past few decades, immunology, biology, and genetics have progressed at a considerable pace due to which the development of cardiological, oncological, and neurological therapies has received a much-needed push. In the past 20 years, multiple radionuclide-based targeted therapies have gradually emerged as one of the most efficient techniques for inflammatory lesions and cancer treatment. At present, an array of therapeutic radionuclides, particularly β− emitters, is increasingly being used across clinics or tested in ongoing clinical trials. At present, within the radiopharmaceutical market, several studies are investigating the potential of 188Re for a broad range of therapeutic applications.

Within the medical sector, the adoption of radiopharmaceuticals is at the nascent stage compared to that of other medicinal products and drugs. However, due to significant advancements and improvements in oncological and neurological therapies, the development of targeted radiopharmaceuticals has gained noteworthy momentum and are creating new growth avenues for stakeholders in the current market landscape. During the 1990s, the healthcare space across developed regions, including North America and Europe witnessed a major overhaul as new regulations and healthcare provisions were introduced. At present, manufacturers or drug developers in the radiopharmaceuticals market are required to comply with guidelines. The demand for radiopharmaceuticals is expected to witness considerable growth during the forecast period, due to their widening applications in oncology, cardiology, neurology, etc. Thus, the global radiopharmaceutical market is expected to reach a value of ~US$ 5.4 Bn by the end of 2027.

To know th escope of our report Get a Sample on Radiopharmaceutical Market

Technetium – 99 Set to Retain Lead Due to Growing Adoption in Diagnostic Procedures

Nuclear medicine has gained significant traction in the past couple of decades. The growing popularity of nuclear medicine can be largely attributed to the availability of 99m Tc– an isotope that is deployed in ~80% diagnostic procedures. At present, nearly 25 million diagnostic procedures are carried out using 99m Tc radiopharmaceuticals and trends suggest that the number is expected to grow at a steady pace annually. One of the major factors that are driving the adoption of Technetium 99 is the availability of short-lived 99m Tc. At present, research and development activities are in full swing to improve the overall production capacity of 99 Mo, which in turn will positively impact the production of 99m Tc.

In the current scenario, 99m Tc is extensively used in multiple diagnostic procedures, including neuroendocrine tumor imaging and pertechnetate for thyroid uptake. The past few years have witnessed a significant rise in research activities that aim to discover new and improved 99m Tc radiopharmaceuticals. 99m Tc is expected to dominate the global radiopharmaceutical market as applications of 99m Tc for dynamic and morphological imaging of liver, renal, bone, etc., are likely to grow during the assessment period. In addition, several radiopharmaceuticals are set to gain acceptance due to their wide availability and economical costs.

Get a glimpse of the in-depth analysis through our Report Brochure

Stakeholders in Current Market Landscape Focus on Complying With Global FDA Guidelines

Stakeholders operating in the current radiopharmaceutical market are required to comply with the published FDA guidelines during the drug development phase. In August 2019, the U.S. FDA published the Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations. A large chunk of companies operating in the current radiopharmaceutical market has predominantly been active participants in the diagnostic sector, wherein fulfilling the stringent regulatory guidelines is the primary area of focus. At present, participants in the radiopharmaceutical market are likely to work in conjunction with companies active in the traditional pharmaceutical space to ensure that their commercialization and drug development strategies align with the FDA guidelines. Some of the major points included by the FDA focus on the evaluation of radiation toxicities, toxicities from the ligand, and data pertaining to product labeling, among others. Stakeholders in the radiopharmaceutical market will continue their pursuit of achieving approval from the FDA to stay relevant in the current market landscape.

Over the past five to six years, the FDA has approved around three advanced radiopharmaceutical therapies– LuDOTATATE for neuroendocrine carcinomas, Radium-223, and MIBG for paraganglioma and pheochromocytoma.

radiopharmaceutical market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

The global radiopharmaceutical market is expected to grow at a CAGR of ~4% during the forecast period. The market growth can be primarily attributed to the increasing focus on the discovery of new radiopharmaceuticals and the soaring adoption rate of Technetium – 99 for diagnostic procedures. Stakeholders should align their product development activities and commercialization strategies in tune with regulatory guidelines laid down by the FDA. Moreover, attaining FDA approval will play an important role in the expansion of the radiopharmaceutical market in the coming years. On the regional front, developed regions including North America and Europe are expected to be at the forefront in terms of the development of new drugs, owing to high concentration of market players, rising investment toward research & development, and robust healthcare ecosystem in these regions.

Radiopharmaceutical Market: Overview

  • The radiopharmaceuticals industry, considered as a sub-branch of pharma industry, has a unique structure. Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases.
  • Radiopharmaceuticals are biologically active molecules labeled by radionuclides, which provide a beneficial source of ionizing radiation for application in diagnostic imaging and therapy
  • Presently, diagnostic labs and hospitals superimpose nuclear medicine images with computed tomography (CT) or magnetic resonance imaging (MRI) to produce special views with the help of radiopharmaceuticals compound. The isotope compound acts as a tracer to produce the image. This is known as image fusion or co-registration. This is one of the factors that boosts the demand for radiopharmaceuticals compounds.

Radiopharmaceuticals: Market Drivers

  • Investment in the development of novel theranostic agents with radioisotopes has increased in the past few years. After decades of neglect by big pharma, radiopharmaceuticals are currently producing significant cancer deals across the globe. This could result in an increase in cancer drugs that can be utilized as both therapies and diagnostics, known as ‘theranostics'. Companies have been emphasizing on the development of drugs employing radioactivity to destroy tumors for the past few years. In 2020, Jubilant Radiopharma invested US$ 25 Mn into SOFIE Biosciences, Inc. to accelerate SOFIE’s state-of-the-art Theranostics Center of Excellence Manufacturing Facility in the U.S.
  • Increase in incidence of cancer across the globe boosts the demand for PET imaging to provide proper treatment. PET, PET-CT test helps to diagnose cancer and provide more information, including whether a tumor is benign or malignant and how well the cancer is responding to treatment. This is an extremely sensitive imaging modality in the detection of malignant tissues and presents higher specificity, which is the primary reason for fewer equivocal scans and better diagnostic results. This drives the demand for radiopharmaceuticals compounds.

Market Segmentation: Radiopharmaceuticals Market

  • In terms of compound, the global radiopharmaceuticals market has been classified into fluorine-18 derivatives, tc-99, Lu-177, Ga-68, Zr-89, 11C-choline, 14C-urea, and others
  • Based on indication, the global radiopharmaceuticals market has been categorized into oncology, neurology, cardiology, and others
  • In terms of system, the global radiopharmaceuticals market has been bifurcated into PET and SPECT
  • Based on end-user, the global radiopharmaceuticals market has been divided into hospitals, diagnostic labs, and others
  • Each of the segments has been analyzed in detail for trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The radiopharmaceuticals market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Radiopharmaceuticals Market

  • In terms of region, the global radiopharmaceuticals market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. The regions have been divided into major countries and sub-regions.
  • The U.S. accounted for major share of the radiopharmaceuticals market in North America in 2020. The country is expected to retain market share during the forecast period. Well-established health care infrastructure and early adoption of advanced imaging equipment are attributed to the U.S.’s dominance of the radiopharmaceuticals market in the region.
  • Asia Pacific is likely to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by players, especially in China and India, are expected to drive the radiopharmaceuticals market in the region.
  • The current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the radiopharmaceuticals market report for the period from 2017 to 2031, along with their CAGRs for the period from 2021 to 2031.
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are likely to help new companies willing to enter the radiopharmaceuticals market and existing companies to increase market share and in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the global radiopharmaceuticals market
  • Leading players analyzed in the radiopharmaceuticals market report are
    • Siemens Healthineers
    • GE Healthcare
    • Advanced Accelerator Applications (a Novartis AG Company)
    • Jubilant Pharma Limited
    • Bayer AG
    • ITM Isotopen Technologien München AG
    • Telix Pharmaceuticals
    • Lantheus Holdings, Inc.
    • Eli Lilly and Company
    • Nihon Medi-Physics
    • Avanos Medical, Inc.
  • Each of these players has been profiled in the radiopharmaceuticals market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Radiopharmaceuticals Market - Scope of Report

TMR’s report on the global radiopharmaceuticals market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides the revenue of the global radiopharmaceuticals market for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global radiopharmaceuticals market from 2021 to 2031.

The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global radiopharmaceuticals market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global radiopharmaceuticals market.

The report includes an elaborate executive summary along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global radiopharmaceuticals market. These serve as valuable tools for existing market players as well as entities interested in participating in the global radiopharmaceuticals market.

The report also delves into the competitive landscape of the global radiopharmaceuticals market. Key players operating in the global radiopharmaceuticals market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global radiopharmaceuticals market that have been profiled in this report.

Key Questions Answered in Radiopharmaceuticals Report

  • What is the sales/revenue generated by radiopharmaceuticals providers across all regions during the forecast period?
  • What are the opportunities in the global radiopharmaceuticals market?
  • What are the major drivers, restraints, opportunities, and threats in the global market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which indication segment is expected to generate the highest revenue globally in 2031?
  • What is the COVID-19 impact on the global market?

Radiopharmaceuticals Market - Research Objectives and Research Approach

The comprehensive report on the global radiopharmaceuticals market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of product.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global radiopharmaceuticals market in terms of compound, indication, system, end-user, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global radiopharmaceuticals market.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Radiopharmaceuticals Market - Segmentation

TMR’s study on the global radiopharmaceuticals market includes information divided into five segments: compound, indication, system, end-user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global radiopharmaceuticals market have been discussed in detail.

Compound
  • Fluorine-18 derivatives
    • Fluorine-18 Fludeoxyglucose (FDG)
    • Fluorine-18 Sodium Fluoride
    • Fluorine-18 Flucicovine
    • Fluorine-18 Florbetapir
    • Fluorine-18 Florbetaben
    • Others
  • Technetium-99
  • Lutetium (Lu) 177
  • Gallium-68
    • Dotatate
    • Dotatoc
  • Zirconium 89
  • 11C-choline
  • 14C-urea
  • Others
System
  • PET
    • Standalone PET Systems
    • Hybrid PET/CT
    • Hybrid PET/MRI
  • SPECT
Indication
  • Oncology
  • Neurology
    • Neurodegenerative Diseases (AD, PD, and Others)
    • Epilepsy
  • Cardiology
  • Others
End-user
  • Hospitals
  • Diagnostic Labs
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceuticals Market

4. Market Overview

    4.1. Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities

    4.3. Global Radiopharmaceuticals Market Analysis and Forecast, 2017–2031

5. Market Outlook

    5.1. COVID-19 Pandemics Impact on Industry

    5.2. Key Industry Events

    5.3. No. of Nuclear Medicine Centers in Major Countries

    5.4. List of FDA Approved Radioisotopes

6. Global Radiopharmaceuticals Market Analysis and Forecast, by Compound

    6.1. Introduction & Definition

    6.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        6.2.1. Fluorine-18 Derivatives

            6.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            6.2.1.2. Fluorine-18 Sodium Fluoride

            6.2.1.3. Fluorine-18 Flucicovine

            6.2.1.4. Fluorine-18 Florbetapir

            6.2.1.5. Fluorine-18 Florbetaben

            6.2.1.6. Others

        6.2.2. Technetium-99

        6.2.3. Lutetium (Lu) 177

        6.2.4. Gallium-68

            6.2.4.1. Dotatate

            6.2.4.2. Dotatoc

        6.2.5. Zirconium 89

        6.2.6. 11C-choline

        6.2.7. 14C-urea

        6.2.8. Others

    6.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Compound

7. Global Radiopharmaceuticals Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        7.2.1. Diagnosis

        7.2.2. Neurology

            7.2.2.1. Neurodegenerative Disease (AD, PD, and Others)

            7.2.2.2. Epilepsy

        7.2.3. Cardiology

        7.2.4. Others

    7.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Indication

8. Global Radiopharmaceuticals Market Analysis and Forecast, by System

    8.1. Introduction & Definition

    8.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        8.2.1. PET

            8.2.1.1. Standalone PET systems

            8.2.1.2. Hybrid PET/CT

            8.2.1.3. Hybrid PET/MRI

        8.2.2. SPECT

    8.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by System

9. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user

    9.1. Introduction & Definition

    9.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        9.2.1. Hospitals

        9.2.2. Diagnostic Labs

        9.2.3. Others

    9.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by End-user

10. Global Radiopharmaceuticals Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Rest of the World

    10.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Region

11. North America Radiopharmaceuticals Market Analysis and Forecast

    11.1. Introduction

    11.2. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        11.2.1. Fluorine-18 Derivatives

            11.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            11.2.1.2. Fluorine-18 Sodium Fluoride

            11.2.1.3. Fluorine-18 Flucicovine

            11.2.1.4. Fluorine-18 Florbetapir

            11.2.1.5. Fluorine-18 Florbetaben

            11.2.1.6. Others

        11.2.2. Technetium-99

        11.2.3. Lutetium (Lu) 177

        11.2.4. Gallium-68

            11.2.4.1. Dotatate

            11.2.4.2. Dotatoc

        11.2.5. Zirconium 89

        11.2.6. 11C-choline

        11.2.7. 14C-urea

        11.2.8. Others

    11.3. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        11.3.1. Diagnosis

        11.3.2. Neurology

            11.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

            11.3.2.2. Epilepsy

        11.3.3. Cardiology

        11.3.4. Others

    11.4. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        11.4.1. PET

            11.4.1.1. Standalone PET systems

            11.4.1.2. Hybrid PET/CT

            11.4.1.3. Hybrid PET/MRI

        11.4.2. SPECT

    11.5. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        11.5.1. Hospitals

        11.5.2. Diagnostic Labs

        11.5.3. Others

    11.6. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America PET-CT Scanner Devices Market Attractiveness Analysis

        11.7.1. By Compound

        11.7.2. By Indication

        11.7.3. By System

        11.7.4. End-user

        11.7.5. By Country

12. Europe Radiopharmaceuticals Market Analysis and Forecast

    12.1. Introduction

    12.2. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        12.2.1. Fluorine-18 Derivatives

            12.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            12.2.1.2. Fluorine-18 Sodium Fluoride

            12.2.1.3. Fluorine-18 Flucicovine

            12.2.1.4. Fluorine-18 Florbetapir

            12.2.1.5. Fluorine-18 Florbetaben

            12.2.1.6. Others

        12.2.2. Technetium-99

        12.2.3. Lutetium (Lu) 177

        12.2.4. Gallium-68

            12.2.4.1. Dotatate

            12.2.4.2. Dotatoc

        12.2.5. Zirconium 89

        12.2.6. 11C-choline

        12.2.7. 14C-urea

        12.2.8. Others

    12.3. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        12.3.1. Diagnosis

        12.3.2. Neurology

            12.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

            12.3.2.2. Epilepsy

        12.3.3. Cardiology

        12.3.4. Others

    12.4. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        12.4.1. PET

            12.4.1.1. Standalone PET systems

            12.4.1.2. Hybrid PET/CT

            12.4.1.3. Hybrid PET/MRI

        12.4.2. SPECT

    12.5. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        12.5.1. Hospitals

        12.5.2. Diagnostic Labs

        12.5.3. Others

    12.6. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Radiopharmaceuticals Market Attractiveness Analysis

        12.7.1. By Compound

        12.7.2. By Indication

        12.7.3. By Systems

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast

    13.1. Introduction

    13.2. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        13.2.1. Fluorine-18 Derivatives

            13.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            13.2.1.2. Fluorine-18 Sodium Fluoride

            13.2.1.3. Fluorine-18 Flucicovine

            13.2.1.4. Fluorine-18 Florbetapir

            13.2.1.5. Fluorine-18 Florbetaben

            13.2.1.6. Others

        13.2.2. Technetium-99

        13.2.3. Lutetium (Lu) 177

        13.2.4. Gallium-68

            13.2.4.1. Dotatate

            13.2.4.2. Dotatoc

        13.2.5. Zirconium 89

        13.2.6. 11C-choline

        13.2.7. 14C-urea

        13.2.8. Others

    13.3. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        13.3.1. Diagnosis

        13.3.2. Neurology

            13.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

            13.3.2.2. Epilepsy

        13.3.3. Cardiology

        13.3.4. Others

    13.4. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        13.4.1. PET

            13.4.1.1. Standalone PET systems

            13.4.1.2. Hybrid PET/CT

            13.4.1.3. Hybrid PET/MRI

        13.4.2. SPECT

    13.5. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        13.5.1. Hospitals

        13.5.2. Diagnostic Labs

        13.5.3. Others

    13.6. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis

        13.7.1. By Compound

        13.7.2. By Indication

        13.7.3. By Systems

        13.7.4. By End-user

        13.7.5. By Country/Sub-region

14. Rest of the World Radiopharmaceuticals Market Analysis and Forecast

    14.1. Introduction

    14.2. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        14.2.1. Fluorine-18 Derivatives

            14.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            14.2.1.2. Fluorine-18 Sodium Fluoride

            14.2.1.3. Fluorine-18 Flucicovine

            14.2.1.4. Fluorine-18 Florbetapir

            14.2.1.5. Fluorine-18 Florbetaben

            14.2.1.6. Others

        14.2.2. Technetium-99

        14.2.3. Lutetium (Lu) 177

        14.2.4. Gallium-68

            14.2.4.1. Dotatate

            14.2.4.2. Dotatoc

        14.2.5. Zirconium 89

        14.2.6. 11C-choline

        14.2.7. 14C-urea

        14.2.8. Others

    14.3. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        14.3.1. Diagnosis

        14.3.2. Neurology

            14.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

            14.3.2.2. Epilepsy

        14.3.3. Cardiology

        14.3.4. Others

    14.4. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        14.4.1. PET

            14.4.1.1. Standalone PET systems

            14.4.1.2. Hybrid PET/CT

            14.4.1.3. Hybrid PET/MRI

        14.4.2. SPECT

    14.5. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        14.5.1. Hospitals

        14.5.2. Diagnostic Labs

        14.5.3. Others

    14.6. Rest of the World Radiopharmaceuticals Market Attractiveness Analysis

        14.6.1. By Compound

        14.6.2. By Indication

        14.6.3. By System

        14.6.4. By End-user

15. Competition Landscape

    15.1. Company Profiles

        15.1.1. Advanced Accelerator Applications (a Novartis AG Company)

            15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.1.2. Growth Strategies

            15.1.1.3. SWOT Analysis

        15.1.2. Siemens Healthineers AG

            15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.2.2. Growth Strategies

            15.1.2.3. SWOT Analysis

        15.1.3. Jubilant Pharma Limited

            15.1.3.1. Company Overview (HQ, Business Segments)

            15.1.3.2. Growth Strategies

            15.1.3.3. SWOT Analysis

        15.1.4. GE Healthcare

            15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.4.2. Growth Strategies

            15.1.4.3. SWOT Analysis

        15.1.5. Bayer AG

            15.1.5.1. Company Overview (HQ, Business Segments)

            15.1.5.2. Growth Strategies

            15.1.5.3. SWOT Analysis

        15.1.6. ITM Isotopen Technologien München AG

            15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.6.2. Growth Strategies

            15.1.6.3. SWOT Analysis

        15.1.7. Telix Pharmaceuticals

            15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.7.2. Growth Strategies

            15.1.7.3. SWOT Analysis

        15.1.8. Lantheus Holdings, Inc.

            15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.8.2. Growth Strategies

            15.1.8.3. SWOT Analysis

        15.1.9. Eli Lilly and Company

            15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.9.2. Growth Strategies

            15.1.9.3. SWOT Analysis

        15.1.10. Nihon Medi-Physics

            15.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.10.2. Growth Strategies

            15.1.10.3. SWOT Analysis

        15.1.11. Avanos Medical, Inc.

            15.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.11.2. Growth Strategies

            15.1.11.3. SWOT Analysis

List of Tables

Table 01: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Compound, 2017–2031

Table 02: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 03: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 04: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 05: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

Table 06: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 07: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 08: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 10: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 11: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

Table 12: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 13: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 14: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 15: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System (PET), 2017–2031

Table 16: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 17: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 18: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 19: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031 

Table 21: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 22: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 23: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 24: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

Table 25: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 26: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 27: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 28: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 29: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

Table 30: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 31: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 32: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 33: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

Table 34: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 35: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 36: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 37: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

Table 38: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 39: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 40: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 41: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

Table 42: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 43: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 44: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Radiopharmaceuticals Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 02: Global PET-CT Scanner Devices Market Value Share, by Region, 2020

Figure 03: Global Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 04: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Technetium-99, 2017–2031

Figure 05: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Gallium-68, 2017–2031

Figure 06: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Fluorine-18 Derivatives, 2017–2031

Figure 07: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Lu-177, 2017–2031

Figure 08: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Zirconium89, 2017–2031

Figure 09: Global Radiopharmaceuticals Market Revenue (US$ Mn), by 11C-choline, 2017–2031

Figure 10: Global Radiopharmaceuticals Market Revenue (US$ Mn), by 14C-urea, 2017–2031

Figure 11: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017–2031

Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 13: Global Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 14: Global Radiopharmaceuticals Market Revenue (US$ Mn), by PET, 2017–2031

Figure 15: Global Radiopharmaceuticals Market Revenue (US$ Mn), by SPECT, 2017–2031

Figure 16: Global Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 17: Global Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 18: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Oncology, 2017–2031

Figure 19: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Cardiology, 2017–2031

Figure 20: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Neurology, 2017–2031

Figure 21: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017–2031

Figure 22: Global Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

Figure 23: Global Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 24: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Diagnostic Lab, 2017–2031

Figure 25: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Hospitals, 2017–2031

Figure 26: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017–2031

Figure 27: Global Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021 -2031

Figure 28: Global Radiopharmaceuticals Market Value Share Analysis, by Region, 2020 and 2031

Figure 29: Global Radiopharmaceuticals Market Attractiveness Analysis, by Region, 2021–2031

Figure 30: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

Figure 31: North America Radiopharmaceuticals Market Value Share Analysis, by Country, 2020 and 2031

Figure 32: North America Radiopharmaceuticals Market Attractiveness Analysis, by Country, 2021–2031

Figure 33: North America Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 34: North America Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 35: North America Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 36: North America Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 37: North America Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 38: North America Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

Figure 39: North America Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 40: North America Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031 

Figure 41: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

Figure 42: Europe Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 43: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 44: Europe Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 45: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 46: Europe Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 47: Europe Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 48: Europe Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 49: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

Figure 50: Europe Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 51: Europe Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031

Figure 52: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

Figure 53: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 54: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 55: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 56: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 57: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 58: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 59: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 60: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031 

Figure 61: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 62: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031

Figure 63: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

Figure 64: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 65: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 66: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 67: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 68: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 69: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

Figure 70: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 71: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031 

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Radiopharmaceuticals Market